New Ventures III

Enterin Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments that address the gut-brain axis in relation to neurodegenerative diseases. The company is advancing its lead product, ENT-01, which aims to reverse constipation associated with Parkinson's disease by displacing aggregates of alpha-synuclein in nerve cells. This mechanism is designed to enhance neural signaling between the gut and the brain, potentially improving outcomes for patients. Enterin also explores synthetic derivatives of endogenous hormones to target misfolded proteins linked to various conditions, including Alzheimer's disease and Type 2 diabetes. Founded in 2014 and based in Philadelphia, Pennsylvania, Enterin seeks to delay the onset and progression of neurodegenerative disorders while contributing to a better understanding of aging and its related pathologies.

Transparency Life Sciences, the first all-digital clinical development services company, harnesses crowdsourcing and mobile health technology to advance biopharma drug candidates through clinical trials with unprecedented patient relevance and efficiency. The TLS model is highly scalable and is designed to increase current industry margins of a wasteful process that often collects irrelevant data. Drug companies will outsource an estimated $38B of clinical trial services to CROs by 2020, with a CAGR of 9-10%. Yet this robust growth masks significant customer dissatisfaction. Sponsors want clinical trials to be better-designed, technologically advanced, patient-centric, and significantly less expensive, yet change has been limited by an inability to see beyond the current outmoded, site-centric model. As a consequence, only select compounds are being developed in humans, leaving many potential important therapies untested in clinical trials. Rapid advances in digital technology and strong regulatory support create a historic opportunity for TLS to catalyze a fundamental transformation, significantly improving the quality of clinical trials while reducing their cost.

Enterin Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments that address the gut-brain axis in relation to neurodegenerative diseases. The company is advancing its lead product, ENT-01, which aims to reverse constipation associated with Parkinson's disease by displacing aggregates of alpha-synuclein in nerve cells. This mechanism is designed to enhance neural signaling between the gut and the brain, potentially improving outcomes for patients. Enterin also explores synthetic derivatives of endogenous hormones to target misfolded proteins linked to various conditions, including Alzheimer's disease and Type 2 diabetes. Founded in 2014 and based in Philadelphia, Pennsylvania, Enterin seeks to delay the onset and progression of neurodegenerative disorders while contributing to a better understanding of aging and its related pathologies.